DNAse treatment does not improve the survival of lupus prone (NZB6NZW) F1 mice
D Verthelyi, N Dybdal, KA Elias, DM Klinman - Lupus, 1998 - journals.sagepub.com
D Verthelyi, N Dybdal, KA Elias, DM Klinman
Lupus, 1998•journals.sagepub.comObjective: To examine the efficacy of deoxyribonuclease I (DNAse) therapy in the (NZB6
NZW) F1 murine model of lupus. Methods: Lupus-prone female (NZB6NZW) F1 mice were
treated daily with 0–15 mg/gof recombinant DNAse for 1–6 months. Parameters including
anti-DNA autoantibody production, activation of cytokine secreting cells, kidney function and
longevity were monitored. Results: DNAse treatment selectively reduced the number of B
cells secreting anti-dsDNA antibodies for approximately one month. However, neither short …
NZW) F1 murine model of lupus. Methods: Lupus-prone female (NZB6NZW) F1 mice were
treated daily with 0–15 mg/gof recombinant DNAse for 1–6 months. Parameters including
anti-DNA autoantibody production, activation of cytokine secreting cells, kidney function and
longevity were monitored. Results: DNAse treatment selectively reduced the number of B
cells secreting anti-dsDNA antibodies for approximately one month. However, neither short …
Objective: To examine the efficacy of deoxyribonuclease I (DNAse) therapy in the (NZB6 NZW)F1 murine model of lupus.
Methods: Lupus-prone female (NZB6NZW)F1 mice were treated daily with 0–15 mg/gof recombinant DNAse for 1–6 months. Parameters including anti-DNA autoantibody production, activation of cytokine secreting cells, kidney function and longevity were monitored.
Results: DNAse treatment selectively reduced the number of B cells secreting anti-dsDNA antibodies for approximately one month. However, neither short-term nor long-term treatment altered cytokine production, delayed the onset or reduced the severity of glomerulonephritis, or prolonged survival.
Conclusion: DNAse treatment initiated before, during, or after the onset of murine lupus did not improve clinical outcome.
Sage Journals